iOmx Therapeutics

iOmx Therapeutics is a clinical-stage biotech company dedicated to transforming cancer treatment through next-generation immune checkpoint therapies. Headquartered in Martinsried near Munich, Germany, iOmx harnesses deep tumor immunology insights to generate novel treatments for the most prevalent solid tumor indications. The company's proprietary iOTarg systematic screening platform identifies unexplored immune evasion biology, which is translated into a growing pipeline of biomarker-enabled drug programs. The company's lead program, OMX-0407, is an orally available first-in-class spectrum-selective inhibitor of SIK (salt-inducible kinase). SIK3 was identified as a novel immune checkpoint target in tumor cells using iOmx's iOTarg platform, with SIK3 known for regulating gene landscapes that cause tumors to evade immune cell killing. iOmx operates with a collaborative, research-driven culture at the heart of one of Europe's leading life science ecosystems. Backed by over $122 million in funding, the company is advancing the next wave of immune checkpoint inhibitors beyond the approximately 150 therapies approved since 2011, aiming to overcome immune evasion mechanisms that limit current treatment options.